Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Taxes (2016 - 2018)

Enanta Pharmaceuticals' Current Taxes history spans 5 years, with the latest figure at $5.9 million for Q4 2018.

  • For Q4 2018, Current Taxes fell 42.89% year-over-year to $5.9 million; the TTM value through Dec 2018 reached $5.9 million, down 42.89%, while the annual FY2018 figure was $1.4 million, 85.07% down from the prior year.
  • Current Taxes reached $5.9 million in Q4 2018 per ENTA's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $16.9 million in Q4 2014 to a low of $1.2 million in Q3 2015.
  • Average Current Taxes over 5 years is $6.8 million, with a median of $5.6 million recorded in 2018.
  • Peak YoY movement for Current Taxes: skyrocketed 31.99% in 2016, then plummeted 85.07% in 2018.
  • A 5-year view of Current Taxes shows it stood at $16.9 million in 2014, then tumbled by 70.76% to $4.9 million in 2015, then plummeted by 40.45% to $2.9 million in 2016, then surged by 248.64% to $10.3 million in 2017, then plummeted by 42.89% to $5.9 million in 2018.
  • Per Business Quant, the three most recent readings for ENTA's Current Taxes are $5.9 million (Q4 2018), $1.4 million (Q3 2018), and $5.4 million (Q1 2018).